Capricor Therapeutics, Inc. (CAPR) - What Are Researchers Thinking About This Stock?

Key Points

• Analysts have a “Hold” consensus on Capricor Therapeutics, with six holds, four buys and one sell among 11 ratings. The average 12-month price target is $30.25, though several firms recently downgraded the stock while Piper Sandler upgraded it to overweight.
• CAPR opened at $6.38, well below its 52-week high of $40.37, with a market capitalization of approximately $370.9 million. The company reported a quarterly loss of $0.70 per share, missing the consensus estimate of a $0.59 loss.
• Capricor is developing cell- and exosome-based therapies, led by deramiocel (CAP-1002) for Duchenne muscular dystrophy. Institutional investors own 21.68% of the company, with several funds recently increasing or initiating positions.

Shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) have been given an average recommendation of "Hold" by the eleven ratings firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, six have given a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $30.25.

CAPR has been the topic of a number of recent analyst reports. Maxim Group lowered Capricor Therapeutics from a "buy" rating to a "hold" rating in a report on Thursday, July 30th. HC Wainwright downgraded Capricor Therapeutics from a "buy" rating to a "neutral" rating in a research note on Monday, July 27th. Roth Capital cut Capricor Therapeutics from a "buy" rating to a "neutral" rating and set a $7.00 target price on the stock. in a research note on Monday, July 27th. LADENBURG THALM/SH SH downgraded shares of Capricor Therapeutics from a "buy" rating to a "neutral" rating in a report on Thursday, July 30th. Finally, Piper Sandler upgraded shares of Capricor Therapeutics from a "neutral" rating to an "overweight" rating in a research report on Tuesday, September 1st.

Capricor Therapeutics Price Performance

CAPR opened at $6.38 on Friday. Capricor Therapeutics has a fifty-two week low of $2.96 and a fifty-two week high of $40.37. The firm has a market capitalization of $370.93 million, a PE ratio of -2.60 and a beta of 0.61. The company's 50-day moving average is $8.06 and its 200 day moving average is $20.60.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The biotechnology company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.11). As a group, analysts expect that Capricor Therapeutics will post -1.71 EPS for the current year.

Institutional Trading of Capricor Therapeutics

Several hedge funds have recently made changes to their positions in the company. Bank of America Corp DE boosted its position in Capricor Therapeutics by 672.0% during the first quarter. Bank of America Corp DE now owns 415,483 shares of the biotechnology company's stock worth $12,631,000 after purchasing an additional 361,664 shares during the period. Montanova Capital LLC raised its position in shares of Capricor Therapeutics by 7.2% in the second quarter. Montanova Capital LLC now owns 4,092,784 shares of the biotechnology company's stock valued at $98,554,000 after purchasing an additional 274,184 shares during the period. Walleye Capital LLC bought a new stake in shares of Capricor Therapeutics in the first quarter valued at approximately $5,397,000. Bank of New York Mellon Corp bought a new stake in shares of Capricor Therapeutics in the second quarter valued at approximately $3,895,000. Finally, Oppenheimer & Co. Inc. lifted its stake in shares of Capricor Therapeutics by 169.1% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 203,781 shares of the biotechnology company's stock valued at $1,930,000 after buying an additional 128,067 shares in the last quarter. 21.68% of the stock is currently owned by institutional investors.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a biotechnology company focused on developing cell and exosome-based therapies for serious diseases. The company's research and development programs are designed to address conditions involving muscle degeneration, inflammation and tissue damage.

Capricor's lead investigational product is deramiocel, also known as CAP-1002, an allogeneic cardiac-derived cell therapy being developed for Duchenne muscular dystrophy. The company has also developed an exosome-based technology platform intended to support the delivery of therapeutic proteins, nucleic acids and other biological materials.

Founded in 2005, Capricor is headquartered in San Diego, California, and conducts its development activities primarily in the United States while working with research, clinical and commercial partners.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.